Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Costanzi-Strauss,E. (2) Strauss,B.E. (2) Palavra-chave Clinical trial (2) Gene therapy (2) Retrovirus (2) Adverse event (1) Animal model (1) Cell cycle (1) Growth arrest (1) Insertional mutagenesis (1) Severe combined immune deficiency (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2007 (1) 1999 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency BJMBR Strauss,B.E.; Costanzi-Strauss,E.. A successful gene therapy clinical trial that also encountered serious adverse effects has sparked extensive study and debate about the future directions for retrovirus-mediated interventions. Treatment of X-linked severe combined immunodeficiency with an oncoretrovirus harboring a normal copy of the gc gene was applied in two clinical trials, essentially curing 13 of 16 infants, restoring a normal immune system without the need for additional immune-related therapies. Approximately 3 years after their gene therapy, tragically, 3 of these children, all from the same trial, developed leukemia as a result of this experimental treatment. The current understanding of the mechanism behind this leukemogenesis involves three critical and cooperating factors,... Tipo: Info:eu-repo/semantics/article Palavras-chave: Retrovirus; Insertional mutagenesis; Severe combined immune deficiency; Gene therapy; Adverse event; Clinical trial. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500002 Efficient retrovirus-mediated transfer of cell-cycle control genes to transformed cells BJMBR Strauss,B.E.; Costanzi-Strauss,E.. The use of gene therapy continues to be a promising, yet elusive, alternative for the treatment of cancer. The origins of cancer must be well understood so that the therapeutic gene can be chosen with the highest chance of successful tumor regression. The gene delivery system must be tailored for optimum transfer of the therapeutic gene to the target tissue. In order to accomplish this, we study models of G1 cell-cycle control in both normal and transformed cells in order to understand the reasons for uncontrolled cellular proliferation. We then use this information to choose the gene to be delivered to the cells. We have chosen to study p16, p21, p53 and pRb gene transfer using the pCL-retrovirus. Described here are some general concepts and specific... Tipo: Info:eu-repo/semantics/article Palavras-chave: Gene therapy; Clinical trial; Retrovirus; Animal model; Cell cycle; Growth arrest. Ano: 1999 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000700016 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco